Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

KBA vs KURE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KURE Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

KURE Overall Winner 6-Pillar Tally: KBA 0 – 0 KURE (6 Tie) Matrix Metrics: KBA 1 – 2 KURE

As of Nov 16, 2026, KraneShares MSCI All China Health Care Index ETF (KURE) is the stronger overall head-to-head candidate over KraneShares Bosera MSCI China A 50 Connect Index ETF (KBA) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). KBA carries a Unified Composite Score of 44.0/100 (HOLD) at $27.83 (N/M Forward P/E, N/A operating margin), whereas KURE carries 50.9/100 (HOLD) at $17.81 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: KBA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.6); meanwhile KURE is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KBA vs KURE
KBA NYSE Arca
KraneShares Bosera MSCI China A 50 Connect Index ETF
Institutional Equity
$27.83
-1.14% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.85β · 19% Vol
Unified Composite Score
44.0 / 100 HOLD
Tech 38.0 Fund 51.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.7%), weak momentum, RSI 34
RSI-14: 33.6 · SMA20: $28.59 · SMA50: $30.22
KURE NYSE Arca Head-to-Head Winner
KraneShares MSCI All China Health Care Index ETF
Institutional Equity
$17.81
-1.66% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.73β · 32% Vol
Unified Composite Score
50.9 / 100 HOLD
Tech 44.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.6%) with fading momentum, RSI 43
RSI-14: 43.2 · SMA20: $18.08 · SMA50: $18.35

6-Pillar Scorecard Institutional Category Breakdown (KBA 0 – 0 KURE)

Columns: Metric · KBA · KURE
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 37.1% (23rd %ile) 28.0% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KBA (1) vs KURE (2)
Institutional Metric KBA KURE Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
0% ($28–$35) 62% ($14–$20) Stronger Trend KURE
Beta / 30D Volatility
Risk Regime
0.85β · 19% Vol 0.73β · 32% Vol Lower Realized Risk KBA
Unified Institutional Score
Composite Signal
44.0 / 100 (HOLD) 50.9 / 100 (HOLD) Higher Composite KURE
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KURE +6.57 pp
KBA: -5.66% · KURE: +0.91%
3M Horizon KURE +12.46 pp
KBA: -17.37% · KURE: -4.91%
6M Horizon KURE +28.16 pp
KBA: -16.85% · KURE: +11.31%
1Y Horizon KBA +0.22 pp
KBA: -9.14% · KURE: -9.36%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KBA vs KURE. Trailing 12-month operating profitability (KBA N/A vs KURE N/A) and valuation multiples (KBA N/M vs KURE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

KBA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
KURE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KBA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 37.1%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KBA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KURE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 28.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KURE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KBA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KURE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KBA vs KURE Key Questions & Quantitative Answers

As of Nov 16, 2026, KraneShares MSCI All China Health Care Index ETF (KURE) is the stronger overall head-to-head candidate over KraneShares Bosera MSCI China A 50 Connect Index ETF (KBA) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). KBA carries a Unified Composite Score of 44.0/100 (HOLD) at $27.83 (N/M Forward P/E, N/A operating margin), whereas KURE carries 50.9/100 (HOLD) at $17.81 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: KBA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.6); meanwhile KURE is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KBA and KURE split Growth & Scale metrics: KBA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with KURE at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, KBA generates N/A in USD-normalized revenue versus N/A for KURE. In operating R&D and SG&A reinvestment, KBA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KURE.

KBA and KURE trade at balanced relative valuation multiples. KBA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas KURE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KBA (N/A ROE) versus KURE (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, KBA carries 37.1% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.85β · 19% Vol realized risk). By comparison, KURE carries 28.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.73β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

KraneShares Bosera MSCI China A 50 Connect Index ETF (KBA) Research Suite

KraneShares MSCI All China Health Care Index ETF (KURE) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.